Accelerate Diagnostics (NASDAQ:AXDX) Stock Rating Upgraded by BidaskClub

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, BidAskClub reports.

Several other analysts have also recently commented on AXDX. ValuEngine upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, December 3rd. JPMorgan Chase & Co. lowered shares of Accelerate Diagnostics from a “neutral” rating to an “underweight” rating and set a $16.00 target price for the company. in a research note on Friday, September 27th. Finally, Piper Jaffray Companies lowered their price target on shares of Accelerate Diagnostics from $22.00 to $19.00 and set a “positive” rating on the stock in a report on Friday, August 9th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. Accelerate Diagnostics currently has a consensus rating of “Hold” and a consensus price target of $18.67.

NASDAQ AXDX opened at $15.88 on Friday. The firm’s 50 day moving average price is $16.13 and its two-hundred day moving average price is $18.55. The company has a debt-to-equity ratio of 12.81, a quick ratio of 20.65 and a current ratio of 21.93. Accelerate Diagnostics has a twelve month low of $10.23 and a twelve month high of $24.00. The stock has a market cap of $867.76 million, a price-to-earnings ratio of -9.80 and a beta of 2.71.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its quarterly earnings results on Thursday, November 7th. The medical research company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. Accelerate Diagnostics had a negative return on equity of 249.46% and a negative net margin of 1,116.69%. The business had revenue of $2.27 million for the quarter, compared to the consensus estimate of $3.15 million. On average, research analysts forecast that Accelerate Diagnostics will post -1.58 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of AXDX. Nuveen Asset Management LLC lifted its holdings in shares of Accelerate Diagnostics by 12.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 448,289 shares of the medical research company’s stock valued at $10,257,000 after buying an additional 51,304 shares during the last quarter. Chicago Capital LLC increased its holdings in Accelerate Diagnostics by 61.3% in the third quarter. Chicago Capital LLC now owns 881,390 shares of the medical research company’s stock worth $16,367,000 after buying an additional 335,111 shares during the last quarter. M&T Bank Corp bought a new position in Accelerate Diagnostics during the second quarter valued at approximately $206,000. First Trust Advisors LP raised its position in Accelerate Diagnostics by 16.7% during the third quarter. First Trust Advisors LP now owns 131,089 shares of the medical research company’s stock valued at $2,434,000 after acquiring an additional 18,757 shares in the last quarter. Finally, TCI Wealth Advisors Inc. bought a new position in Accelerate Diagnostics during the third quarter valued at approximately $1,032,000. 54.35% of the stock is currently owned by institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Read More: Blue-Chip Stocks

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.